Summary.-Monoclonal antibodies to epithelial -cell antigenic determinants, labelled with 1231 and 1251, were administered parenterally to immunodeficient mice bearing human tumours derived from a human cancer cell line. Anterior, posterior and lateral radioscans of the body were taken with a gamma scintillation camera at various times from immediately to 65 days after injection. Visual displays of the images were processed by standard computer techniques. The model used a human colon-cancer cell line, HT29, and the monoclonal antibody, AUA1, which is specific to an epithelial proliferating antigen. Tumour detection was achieved in all the mice. The smallest tumour detectable appeared to be about 1 mm in diameter. The degree of antibody uptake in a tumour depended on its size and the blood supply of its surrounding tissues We believe that the technology and skills are now available for accurate radioimmunodetection of cancer in man.
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THE LOCALIZATION OF CANCER in man using radionuclides has so far been nonspecific, relating, for example, to a focal defect on a liver scan or a focal area of increased activity on a bone or a brain scan. The recognition of tumour-associated and highly tissue-specific antigens, the development by Kohler and Milstein (1975) of the monoclonal-antibody technique and the regular production by A.E.R.E. Harwell of pure iodine-123 bring together the requirements for accurate radioimmunodetection of cancer in man.
Radioimmunodetection of cancer is not a new field and its potential clinical use has been demonstrated by many authors in the past (Korngold & Pressman, 1964; Mach et al., 1980; Goldenberg et al., 1980; Begent et al., 1980; Moshakis et al., 1981a) . This study, using a human cancer cell line in an animal model and a pure 1231-1 labelled monoclonal antibody, extends previous results.
METHODS

JMonoclonal antibodies
The monoclonal antibody AUA1 was obtained from Arklie (1981) , who raised it in the conventional fashion by immunizing BALB/c mice with the colon-carcinoma cell line LoVo (Stragard et al., 1980) . This antibody is specific for an epithelial proliferating antigen as found by testing in binding assays against epithelial-cancer cell lines and in sections using immunofluorescent and immunoperoxidase techniques and involving normal and malignant epithelial tissues (Arklie, 1981) . Using immunoperoxidase staining, this antibody stains positively human colon carcinomas as well as the villi of normal colon. It is not a tumour-specific antibodv, but it is tissue-specific and tumour-associated.
The negative-control monoclonal antibody M236 was obtained from Dr R. Knowles, who raised it against the lymphoblastoid cell line MOLT4. (MinowAada et al., 1972) . This antibody has been found to be specific for cells of the T-lymphocyte lineage and does not react w%Aith cells of epithelial origin.
Both antibodies were grown in bulk, either as ascites in mice or as supernatants in tissue culture. The average concentration of antibodies -was 2 mg/ml in ascites and 10 Mtg/ml in supernatant.
Characterizatioit of imim.nunoglobulin AUA1 and M236 were found to belong to the IgGi subclass by Ouchterlony double diffusion. (Ouchterlony, 1970) . Preparation of pure IgG.-Ammonium sulphate precipitation (Kekwick, 1940) w%Aas used as a first step in separating the bulk of albumin from the immunoglobulin. The precipitate was then filtered through a, protein-ASepharose column and the IgGi subfraction was eluted using a citrate buffer (pH 6 0) (Ey et al., 1978) . The purity of the IgG1 was checked using polyacrylamide-gel electrophoresis (Laemmelli, 1970) and isoelectric focusing (Awdeh et al., 1968) . Both techniques showed a characteristic monoclonal pattern, indicating a highly purified product.
Binding to cells.-The reactivity of the fractions containing AUA1 and M236 was determined by binding to HT29 and MOLT4 cells in a radioimmune binding assay (Williams, 1977 ). Both antibodies were tested for reactivity, and were found to bind to their respective target cells after inodination.
Iodination of monoclonal antibodies.-The IgGI fractions were iodinated with 1231 or 1251 using 2 methods: Chloramine T (Greenwood et al., 1963) and Jodogen (Salacinski et al., 1980) . Both techniques w%ere similar in efficacy, yielding about 80% incorporation of iodine into immunoglobulin when equimolar amounts of iodine and immunoglobulin were used in the initial reaction. The chloramine T method was as follows: 25 ul of antibody at 1 mg/ml in citrate buffer (pH 6.0) mixed with 25 gtl of phosphate buffer (0.3M, pH 7-4) were reacted with 10 ,ul of 1251 (37 MBq, Amersham, 1 mC code 1 IMS 30 and 10 tl of chloramine T (2 mg/ml) in phosphate buffer (0-3M, pH 7.4).
The reaction solution was mixed for 2 min.
Free iodine w%ras removed by gel filtration. using a G50 Sephadex column and eluting with phosphate-buffered saline (PBSA)
The G50 Sephadex wxas prewashed with 1% BSA in PBSA. The iodogen method was as follows: 2 ml of iodogen (40 ,ug/ml) in dichloromethane wAvas allowed to dry in small conical propylene tubes. Antibody, phosphate buffer and 125 at the same amounts as used for the chloramine T method were added and left for 20 min. Again free iodine was removed using a G50 Sephadex column. In both techniques a specific activity of 5 mqB ,ug was achieved.
When iodinating with 1231 (A.E.R.E., Harwell) the conditions were the same as for 1251, except that phosphate buffer (0-3M, pH 5.5) was used to adjust the final pH to 7 4, and 100 ,u of 1231 in 0-04M NaoH (pH 12.4) equivalent to 37 MBq (]mG) were added. The iodination efficiency using 1231 was less then when using 125, probably because 1231 iS more dilute (it has a molarity of 4x 1O-8M compared to 125I of 5x 1O-5M). The antibodies were injected into mice on the same day that they were iodinated.
The different iodine isotopes 1231 and 1251 were used for different purposes. 1231 gives maximum clarity of tumours at any depth of tissue. Although it has a half-life of only 13 h. adequate views were obtained up to 96 h after injection. The principal radiation of 1231 is a y-ray with an energy of 160 keV, which is ideally suited for present-day y-cameras.
125 is used to examine the long-term behaviour of the labelled monoclonal antibody in the tumour. Studies with 125 have been carried out sequentially up to 65 days from injection of antibody. 125 also offers the opportunity for autoradiographs on tumour masses and other organs.
The monoclonal antibody M236 labelled with 125 and 1231 was used as a negative control. A monoclonal antibody of the same immunoglobulin subclass (IgGi) provides the most appropriate comparison between specific and nonspecific uptake. Subtraction of the 2 results (i.e. the M236 from the AUA1) wNas not found to be necessarv for visualization of the tumour.
Immunoperoxidase staining
Formalin-fixed and paraffin-embedded sections of tumours and other organs were first dewaxed and then fixed in alcohol. Sections were tested in triplicate: 1 with the monoclonal antibody of interest (AUA1), 1 w%rith the negative-control antibody (M236) and 1 without antibody to assess the nonspecific background staining (Arklie, 1981) .
Autoradiography
The selective localization of injected iodinated monoclonal antibody in tumours, in contradistinction to the absence from other normal organs, is demonstrated by autoradiography (ARG). Formalin-fixed and paraffin-embedded sections of tumours and other organs are first dewaxed and then fixed in alcohol. ARGs were prepared using Ilford K5 fluid emulsion. After drying in air the sections were exposed for 7-30 days at 4°C. The sections were then developed, fixed and stained with haemotoxylin for light microscopy.
Scanning
Nineteen nude mice and 1 nude rat were tested. Before scanning, the animals were anaesthetized with i.p. pentobarbitone. The amount of injected radiolabel ranged from 0-08 mC (3 MBq) to 0-3 mC (11 0 MBq) forl.231, and from 0-1 mC (3-7 MBq) to 20 mC (740 MBq) of 1251. The amount of antibody administered ranged from 2 jig to 500 ,ug. (500 ,g, equivalent to 740 MBq = 20 mC was given only once to a nude rat as a therapeutic attempt). All the mice were injected with antibody in the range 2-10 pg. Imaging was performed with a standard y-camera fitted with a highsensitivity collimator. The camera was linked to a computer with data display. The counts at different regions of interest (i.e. total body, tumour, blood pool) were then calculated and expressed as a percentage of the initial injected amount. For each selected region of interest, a narrow circumferential region was used as a background area to allow estimation of uptake. This technique enables us to quantitate the uptake of antibody at different regions of interest sequentially, and thus get information both on the uptake of the antibody and also on its catabolism and excretion without having to sacrifice the animal. If, for example, one counts the activity over a tumour region and the tumour is then removed and counted using standard scintillation counting, the same count is obtained on both occasions. Thus this technique, though different in offering an opportunity to study the dynamic behaviour of the radiolabelled antibody, does not give different counts from conventional scintillation counting.
RESULTS
Tumour localization was achieved in all the animals. A typical radioscan is shown in Fig. 1(a) , where a mouse with an i.m. HT29 tumour (Fogh et al., 1977) on its left leg was scanned at 20 min and 2, 18 and 48 h after an i.v. injection of AUA1 monoclonal antibody labelled with 1231. As can be seen, after 18 h the tumour is clearly visible. Fig. 1(b) shows scans of the same mouse after being injected with the nonspecific antibody M236 labelled with 125J, also scanned at 20 min and 2, 18 and 48 h. The scans taken at 18 and 48 h show some activity over the tumour region, calculated to be 1% and 0.1% of the injected amount, respectively. This uptake is spurious, because 30% of the counts arising from AUA1 1231 are picked up in the 125I channel. However, to some extent there is nonspecific uptake of Ig, as demonstrated by other experiments in which tumour-bearing mice were injected with the nonspecific antibody alone. The nonspecific uptake of antibody will depend on at least 2 factors. Firstly, tumours may have Fc receptors and thus be able to capture some Ig if it is aggregated. Secondly, the vascularity of a tumour will influence its blood supply and also the nonspecific trapping of antibody. We have performed similar experiments in other tumour models, using a trophoblastic cell line (Dosmi) and neuroblastoma cell line (TR14) and found that both of these grow as vascular tumours and have much higher uptake of nonspecific antibodies. In the case of the trophoblastic cell line Dosmi we found no difference between nonspecific and specific antibody uptake. When Dosmi cells were grown as i.m. tumours, we obtain 30-40% uptake of the injected amount of any radiolabelled antibody. This is probably due to the special properties of the trophoblast for example, their large number of Fc-receptor sites (McNabb et al., 1976 Fig. 2 shows the uptake of both specific and nonspecific antibodies. The highest and fastest specific antibody uptake was seen in the i.m. tumours, with uptake ranging from 0.5% to 25% of the injected dose (mean -60%). This level was reached between 4 and 18 h after injection (see Fig. 2 ). The average uptake of the nonspecific antibody was -0-15% of the injected dose.
Both the i.p. and s.c. tumours had an uptake of 0 .5 %, but it is interesting to note that in the i.p. tumours the antibody localized faster (i.e. within 24 h) while in the s.c. tumours the uptake was slower, taking up to 6 days to reach maximum level. There was no measurable (i.e. <0.1%) uptake of nonspecific antibody in the s.c. tumours. The best pictures are seen after a period ranging from 4 h to 1 week, depending again on the site of the tumour. For example, most of the i.m. tumours were clearly seen after 18 h, because the uptake in the tumour, after reaching its peak, remained relatively high for much longer than in the rest of the body, whence it was mostly cleared by 18 h, thus leaving a "hotter" spot in the tumour area. These results could also be expressed in terms the surrounding stroma, due to nonspecific background uptake. The distribution is further confirmed by ARG on dissected tumours and other mouse organs.
In Fig. 4 a clear outline of the tumours can be seen against the normal mouse tissue. Mouse organs such as liver and spleen were used as negative controls, and no ARG evidence of antibody was found. It is of interest that other workers (Moshakis et al., 1981b) antibodies gives clearer results than conlabel has been found for ventional polyclonal antisera. The adys. After this the tumours vantages of monoclonal antibodies are nd the mice had to be killed. however not realised until they are purified y of the tumour masses to minimize the presence of other proteins, cl as was that of several whether these be albumin or other that were invaded by tum-immunoglobulins, in order to avoid nontoxylin and eosin, as well specific uptake of radiolabel. The tumour oxidase staining using newly uptake of the radiolabel varied between ly, were used. Fig. 3 al., 1980) . to negative (light blue)
Using the described methods of purifiuse stroma. This is particu-cation, the tumour uptake was enough at the outer margin of the to make any techniques for tumour site re it is most active meta-enhancement and visualization (Deland where specific for epithelial cell surfaces, so there is no specific or prolonged uptake in the blood pool and relatively constant retention on the tumour surface, a point that may be significant to the possible therapeutic use of this technique. Radiolabelling with 123I is ideally suited for present-day y-camera use, because with this isotope the clearest pictures are seen with the minimum radiation to the host. This, of course, will be even more important in the human situation, where deep seated lesions are sought, with minimal biohazard from radiation to patient and staff.
Finally, the combination of monoclonal antibodies, perhaps administered through different routes (e.g. i.v. and intralymphatically) may give a more complete picture of size and site of tumour and its metastases, however small.
Currently, there exist several monoclonal antibodies, e.g. A3 and F3 (TaylorPapadimitriou, et al., 1981; Arklie, et al., 1981 ) (specific to epithelial tissues and associated with adenocarcinomas of breast) that when used in combination may selectively localize to primary (F3) and metastatic (A3) breast adenocarcinomas. Furthermore, the possibility of therapy using armed monoclonal antibodies with P-emitting radionuclides, toxins or drugs should now be explored.
